Rapid Lymph Accumulation of Polystyrene Nanoparticles Following Pulmonary Administration

ABSTRACT Purpose Pulmonary administration of polymeric nanoparticle drug delivery systems is of great interest for both systemic and local therapies. However, little is understood about the relationship of particle size and pulmonary absorption. We investigated uptake and biodistribution of polystyr...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutical research Vol. 30; no. 2; pp. 424 - 434
Main Authors Mohammad, Abdul Khader, Amayreh, Lenah K., Mazzara, John M., Reineke, Joshua J.
Format Journal Article
LanguageEnglish
Published Boston Springer US 01.02.2013
Springer
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:ABSTRACT Purpose Pulmonary administration of polymeric nanoparticle drug delivery systems is of great interest for both systemic and local therapies. However, little is understood about the relationship of particle size and pulmonary absorption. We investigated uptake and biodistribution of polystyrene nanoparticles (PN) of 50 nm, 100 nm, 250 nm, and 900 nm diameters in mice following administration to lungs via pharyngeal aspiration. Methods The amount of PN in tissues was analyzed by gel permeation chromatography (GPC). Results At 1 h, larger diameter PN (250 nm and 900 nm) had the highest total uptake at around 15% of administered dose, whereas the smaller diameter PN (50 nm and 100 nm) had uptake of only 5–6%. However, at 3 h, the 50 nm PN had the highest total uptake at 24.4%. For each size tested, the highest nanoparticle deposition was observed in the lymph nodes (LN) as compared to other tissues accounting for a total of about 35–50% of absorbed nanoparticles. Conclusion PN size impacts the rate and extent of uptake from lungs and, further, the extent of LN deposition. The extent of uptake and lymph distribution of the model, non-degradable PN lends potential to pulmonary administered, biodegradable polymeric nanoparticles for delivery of therapeutics to regional lymph nodes.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0724-8741
1573-904X
DOI:10.1007/s11095-012-0884-4